The Skeletal Muscle as an Active Player Against Cancer Cachexia
- PMID: 30833900
- PMCID: PMC6387914
- DOI: 10.3389/fphys.2019.00041
The Skeletal Muscle as an Active Player Against Cancer Cachexia
Abstract
The management of cancer patients is frequently complicated by the occurrence of cachexia. This is a complex syndrome that markedly impacts on quality of life as well as on tolerance and response to anticancer treatments. Loss of body weight, wasting of both adipose tissue and skeletal muscle and reduced survival rates are among the main features of cachexia. Skeletal muscle wasting has been shown to depend, mainly at least, on the induction of protein degradation rates above physiological levels. Such hypercatabolic pattern is driven by overactivation of different intracellular proteolytic systems, among which those dependent on ubiquitin-proteasome and autophagy. Selective rather than bulk degradation of altered proteins and organelles was also proposed to occur. Within the picture described above, the muscle is frequently considered a sort of by-stander tissue where external stimuli, directly or indirectly, can poise protein metabolism toward a catabolic setting. By contrast, several observations suggest that the muscle reacts to the wasting drive imposed by cancer growth by activating different compensatory strategies that include anabolic capacity, the activation of autophagy and myogenesis. Even if muscle response is eventually ill-fated, its occurrence supports the idea that in the presence of appropriate treatments the development of cancer-induced wasting might not be an ineluctable event in tumor hosts.
Keywords: adaptive response; energy metabolism; muscle wasting; myogenesis; oxidative stress; protein turnover.
Figures



Similar articles
-
Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):345-54. doi: 10.1002/jcsm.12050. Epub 2015 Jul 7. J Cachexia Sarcopenia Muscle. 2016. PMID: 27239411 Free PMC article.
-
Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia.Front Physiol. 2017 Apr 19;8:213. doi: 10.3389/fphys.2017.00213. eCollection 2017. Front Physiol. 2017. PMID: 28469577 Free PMC article.
-
Mediators of cachexia in cancer patients.Nutrition. 2019 Oct;66:11-15. doi: 10.1016/j.nut.2019.03.012. Epub 2019 Mar 29. Nutrition. 2019. PMID: 31177056 Review.
-
Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies.J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1150-1167. doi: 10.1002/jcsm.13073. Epub 2023 Mar 2. J Cachexia Sarcopenia Muscle. 2023. PMID: 36864755 Free PMC article. Review.
-
The Redox Balance: A Target for Interventions Against Muscle Wasting in Cancer Cachexia?Antioxid Redox Signal. 2020 Sep 10;33(8):542-558. doi: 10.1089/ars.2020.8041. Epub 2020 Mar 5. Antioxid Redox Signal. 2020. PMID: 32037856 Review.
Cited by
-
Growth hormone secretagogue receptor-1a mediates ghrelin's effects on attenuating tumour-induced loss of muscle strength but not muscle mass.J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1280-1295. doi: 10.1002/jcsm.12743. Epub 2021 Jul 15. J Cachexia Sarcopenia Muscle. 2021. PMID: 34264027 Free PMC article.
-
The ubiquitin-proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders.J Physiol Sci. 2020 Sep 16;70(1):40. doi: 10.1186/s12576-020-00768-9. J Physiol Sci. 2020. PMID: 32938372 Free PMC article. Review.
-
Exosomal Plasminogen Activator Inhibitor-1 Induces Ionizing Radiation-Adaptive Glioblastoma Cachexia.Cells. 2022 Oct 1;11(19):3102. doi: 10.3390/cells11193102. Cells. 2022. PMID: 36231065 Free PMC article.
-
Impact of temporalis muscle thickness in elderly patients with newly diagnosed glioblastoma treated with radio or radio-chemotherapy.Radiol Med. 2022 Aug;127(8):919-924. doi: 10.1007/s11547-022-01524-2. Epub 2022 Jul 18. Radiol Med. 2022. PMID: 35849309
-
Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers.Front Cell Dev Biol. 2021 Sep 14;9:719643. doi: 10.3389/fcell.2021.719643. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34595171 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources